Citius Pharmaceuticals Inc

NASDAQ:CTXRUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

Contact Information

Headquarters

11 Commerce Dr Fl 1CRANFORD, NJ, United States 07016-3501

Phone

908-967-6677

Fax

---

Executives

Executive Chairman of the Board, Chief Executive Officer, Company Secretary

Leonard Mazur

Executive Vice Chairman of the Board

Myron Holubiak

Chief Financial Officer, Chief Business Officer

Jaime Bartushak

Chief Medical Officer, Executive Vice President

Myron Czuczman

Vice President - Corporate Communications and Investor Relations

Ilanit Allen